The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Significant gains have been made in the appreciation of pediatrics as an important population in which rationale pharmacotherapy guidance is warranted but often currently lacking. Although the regulatory framework for major improvements in pediatric drug development was implemented in Europe a decade later than the United States, recent efforts, including the 2007 “Better Medicines for Children” initiative, indicate that the awareness of this problem is indeed a global phenomenon. Nevertheless, there still remains a gap between the awareness and the implementation of rationale and scientifically based drug development and applied pharmacotherapy in children. Specifically, a vision of how best to move from empiricism toward a plan that incorporates biologic knowledge about the maturation of physiologic processes as well as the drug‐ and disease‐specific knowledge generated from drug development and applied pharmacotherapy in adults must evolve from the present intentions. Modeling and simulation approaches can facilitate such a vision that ultimately should provide benefit to pediatric patients. Although recent examples of pediatric in silico approaches are compelling, their ultimate value may be in the identification of data and studies that better guide drug therapy and in the education of pediatric caregivers to the principles of clinical pharmacology that underlie optimal pharmacotherapeutic decisions in children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795 · cited 1×
“64 Although there is controversy about the correlation between vancomycin serum concentrations and toxicity, 65,66 it has been suggested repeatedly that vancomycin trough concentrations are predictive for nephro toxicity.”
BackgroundJohnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530 · cited 1×
“37,81,82 Midazolam (MDZ) undergoes extensive metabolism by the cytochrome P4503A subfamily (CYP3A4 and CYP3A5) to a major hydroxylated metabolite, 1-hydroxy midazolam (1-OHMDZ), and a minor metabolite, 4-hydroxy midazolam (4-OHMDZ).”
BackgroundFluconazole prophylaxis against fungal colonization and infection in preterm infants.
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010494 · Cited by 523 · cited 1×
“49,50 At least 90% of the most preterm infants achieved the minimum AUC of 400 mg ⋅ h/L. Figure 3 illustrates the ability of the model to generalize across developmental stage and organ status (renal insufficiency) with respect to exposure metrics used to judge the efficacy of fluconazole in…”
BackgroundBarter, Z., Bayliss, M., Beaune, P., Boobis, A., Carlile, D., Edwards, R., Brian Houston, J., Lake, B., Lipscomb, J., Pelkonen, O., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315053 · Cited by 459
Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children
Edginton, A. N., Schmitt, W., & Willmann, S. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645100-00005 · Cited by 357 · cited 2×
“37,81,82 Midazolam (MDZ) undergoes extensive metabolism by the cytochrome P4503A subfamily (CYP3A4 and CYP3A5) to a major hydroxylated metabolite, 1-hydroxy midazolam (1-OHMDZ), and a minor metabolite, 4-hydroxy midazolam (4-OHMDZ).”
BackgroundPharmacokinetic/Pharmacodynamic Modeling in Drug Development
Sheiner, L. B., & Steimer, J.-L. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.67 · Cited by 351
Prediction of intestinal absorption: comparative assessment of gastroplus™ and idea™
Parrott, N., & Lavé, T. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00132-x · Cited by 170
Willmann, S., Lippert, J., & Schmitt, W. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.159 · Cited by 140 · cited 3×
“Simcyp, 76,77 PKSim, 78 and GastroPlus 79,80 are probably the most well-established software solutions in this area, all of which have ongoing efforts to incorporate developmental and maturational factors into their algorithms to cope with the challenge of predicting pediatric dose-exposure relationships.”
BackgroundPharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life
Saxén, H., Hoppu, K., & Pohjavuori, M. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.147 · Cited by 127 · cited 2×
“47 Prior to the design of this trial, the existing published data were generously provided by the original investigators 46 and used to develop an initial POPPK model with which simulations to optimize the study were conducted.”
Method
Cited by
Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
Diao, L., & Meibohm, B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0079-0 · Cited by 369
Self-citationThe Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
Huang, S.-M., & Rowland, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.320 · Cited by 150
Janssen, J. M., Zwaan, C. M., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.050 · Cited by 6
Metadata
- Authors
- Läer, S., Barrett, J. S., & Meibohm, B.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-08
- Volume
- 49
- Issue
- 8
- Pages
- 889-904
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2133840634
- Cited by
- 70
- References
- 9
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy. https://app.cochat.ai/papers/10.1177/0091270009337513
- The paper
- Läer, S., Barrett, J. S., & Meibohm, B. (2009). The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009337513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.